GlassScriptPhysician profile
Robert G Mobley
NPI 1467435537
$2,109.39
in general payments reported to CMS, 2019-2025
18 companies · $96.31 in 2025
The $96.31 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $885 · 2020: $339 · 2021: $80.90 · 2022: $81.51 · 2023: $344 · 2024: $283 · 2025: $96.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $723.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $639.49 | 2019-2024 | Rocklatan, Clareon, Total30 |
| Topcon Healthcare, INC. | $251.66 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $165.07 | 2019-2021 | |
| Allergan, INC. | $162.58 | 2020-2022 | |
| Abbvie INC. | $130.96 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $126.66 | 2019-2023 | Eylea Hd |
| Aerie Pharmaceuticals, INC. | $113.92 | 2019 | |
| Optos, INC. | $92.38 | 2019 | |
| Shire North American Group INC | $76.17 | 2019 | |
| Omeros Corporation | $71.37 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $45.41 | 2024 | Xdemvy |
| Genentech USA, INC. | $44.42 | 2022-2024 | Vabysmo |
| Ocular Therapeutix, INC. | $41.20 | 2019-2025 | Dextenza |
| Novartis Pharmaceuticals Corporation | $39.58 | 2020 | |
| Harrow Eye, LLC | $38.12 | 2025 | Iheezo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $33.48 | 2024 | Rayone Emv, Omidria, Rayone Aspheric |
| Biotissue Holdings INC. | $21.66 | 2023 | |
| Bausch & Lomb Americas INC. | $15.26 | 2023 | Miebo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mobley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.